Newsroom.

What GLP Chart is

GLP Chart is an independent GLP-1 price tracker. We follow 27 US programs across telehealth, compounded, manufacturer-direct and retail. Every Monday we check each price against the program's own published pricing, and we score every program on a published 50-point framework. No program pays to be listed. No program can pay to move its rank. Some visit links earn us a commission.

Quotable stats, ready to paste

Every figure here is checked against the program's published pricing and the manufacturer list price. Quote any of it, with attribution. Want the source link behind a number? Email press@glpchart.com and we will send it.

Prices are cash-pay before insurance unless noted. Branded retail figures are the manufacturer list price. Compounded figures are 503A pharmacy cash-pay through the telehealth programs we track.

Free data

Free to use and free to cite, attribution appreciated. Everything below is published under CC BY 4.0.

• Price Index CSV (August 2026) every program, every drug, maintenance price, lock-in, score and the five sub-scores.
• Price-history CSV and JSON dated month-over-month snapshots, so you can chart a program's price moves over time.
• GLP-1 Price Report 2026 the editorial report behind the numbers: the cash-pay spread, teaser-versus-maintenance gaps, compounded versus branded, and every price move so far this year.
• Price Index PDF (June 2026 edition) the chart and methodology in one file, ready to send to a source.
• facts.json the machine-readable canonical fact sheet, for AI search and automated citation.

The live numbers, as of August 24

These come straight out of the data and refresh every Monday, so your quote stays current. They use the all-in cash-pay basis: the monthly figure already includes the maintenance-dose medication.

• 27 US GLP-1 telehealth programs tracked on the chart.
• $149/mo the cheapest all-in cash-pay total, drug included (Strut Health).
• $299/mo the median all-in cash-pay total across all programs.
• $448/mo the most expensive all-in cash-pay total (LifeMD).
• 3.0x the price ratio between cheapest and most expensive on the same basis.

All-in means the monthly figure includes the maintenance-dose medication. Membership-only fees (drug billed separately) and insurance-dependent copays (a with-coverage price, not a cash total) are not counted as the cheapest cash-pay all-in, the same basis the Price Index uses.

See the full August 2026 Price Index for the per-program breakdown, or pull the change-log JSON feed directly.

What moved this week

Every Monday we check all 27 programs against their published pricing. Here is what moved: who raised or cut a price, who added or dropped a lock-in, who restructured, who left the US. Every entry is dated to the week we verified it.

Spotted something? If you catch a program quietly raising a price or slipping in a new lock-in before we do, tell us at tips@glpchart.com. We verify and date every report.

Price Index, August 2026

Download the source data or embed the live widget.

• CSV every program, every drug, maintenance price, lock-in, score and five sub-scores.
• PDF report (June 2026 edition) editorial summary with methodology and the full chart, ready to send to a source.
• Full landing page the live, sortable chart with every program and sub-score.

Embed the widget. One iframe, no JavaScript, no tracking cookies. It pulls the latest top-five programs by cash-pay maintenance price and refreshes every Monday.

<iframe src="https://glpchart.com/price-index/embed/" width="100%" height="380" frameborder="0" loading="lazy" title="GLP Chart Price Index, August 2026" style="border: 1px solid #eaeaea; border-radius: 2px; max-width: 720px;"></iframe>

Renders in WordPress, Webflow, Ghost, Substack and any CMS that allows raw HTML. For paste-ready quote cards and the journalist FAQ, see the Price Index page.

How we verify

Every price is verified against the program's own published pricing page, checked every Monday:

• We read the maintenance-dose figure straight off the program's pricing page. If a site blocks automated access, we confirm the number through a web search of the program's own materials.
• When a program runs a separate cash-pay rail and an insurance-routed rail, we report the cash-pay number.

Want to cite a specific number? Email press@glpchart.com and we will send the published source, a link to the program or manufacturer pricing page it came from.

For the scoring framework and the five sub-score definitions, see the methodology page. For how we stay independent of the programs we rank, see why trust us.

A nameable expert, on the record

John Samaras, founder and editor.He started GLP Chart after overpaying for a GLP-1 himself, and has covered the US GLP-1 telehealth category full time since 2026. He’s in Austin, Texas (US Central) and goes on the record by name. Reach him at press@glpchart.com or on WhatsApp at +1 (646) 305-3003. More on his LinkedIn and the About page.

Topics he can speak to:

• The economics of compounded GLP-1. Why the supply moved off the shortage list, how 503A pharmacies adapted, what the “personalized formulation” trend means in 2026.
• Insurance prior-authorization mechanics. The documented criteria, the appeal pathways, the denial rate by carrier where available.
• Wegovy vs Zepbound. Clinical trial versus real-world adherence, dose-response curves, the dropout problem in both pivotal clinical trials.
• Maintenance dosing and discontinuation. What happens when patients stop, the regain curve, what industry is and is not saying about lifetime use.
• Telehealth program differentiation. Which models work, which are racing to the bottom on price, which are quietly upselling into supplements and coaching.

Published elsewhere

• The price of Ozempic is a meaningless phrase The Health Care Blog, July 16, 2026.
  One molecule sells in five forms at seven prices, from a $25 copay to about $1,000 a month at the counter. Two numbers decide what a patient actually pays: the maintenance-dose total after the teaser price expires, and the fees stacked on top of the medication.

Request data or a quote

Tell us the stat or table row you want sourced and we will send the underlying file. We reply within one business day, US Central time.

John Samaras, founder and editor. Email press@glpchart.com or message him on WhatsApp at +1 (646) 305-3003.

Citation terms

The GLP Chart Price Index and change-log are published under Creative Commons CC BY 4.0. Reuse any number, table row, chart or quote card with attribution and a link back. Suggested citation:

For source-level documentation (links to the published program and manufacturer pricing pages each figure came from), email press@glpchart.com or message us on WhatsApp +1 (646) 305-3003. For embargoed pre-release of next quarter's figures, reach us at least 72 hours before publication.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact